#melanoma
Latest news and interesting information about melanoma.
Brenetafusp Shows Promise in Melanoma
Immunocore's brenetafusp showed 14.3-month median overall survival in Phase 1/2 melanoma trial, supporting Phase 3 development.
Melanoma: Who is in the risk group?
Melanoma is an aggressive cancer. Who is at risk? Learn about symptoms and prevention.
Iovance Biotherapeutics: stock gains on melanoma data
Iovance Biotherapeutics stock gains momentum on real-world melanoma data for Amtagvi. Despite losses, analysts see upside from manufacturing efficiencies and label expansion.
Regeneron melanoma drug trial misses primary endpoint
Regeneron's melanoma drug trial fails primary endpoint: fianlimab+cemiplimab combination did not significantly improve progression-free survival vs pembrolizumab.
...